by Brad N. Taylor, Ph.D. | Dec 20, 2022
In celebration of the holidays, we take a look back at some of the most exciting events and achievements of the year…and a look forward to what the New Year will bring. Science enthusiasts everywhere, your attention please! Today we thank the hardworking team at...
by Brad N. Taylor, Ph.D. | Oct 27, 2022
Top 10 Cell and Gene Therapy Conferences That Deserve Your Consideration As the number of cell and gene therapies both in development and approved continue to increase, so too do the number of conferences held and events pertaining to them. Whether you are a...
by Brad N. Taylor, Ph.D. | Jul 12, 2022
Scientists are invested in making the world a better place to live— so how do we address the fact that the pharmaceutical industry has a sustainability problem? Read below for steps you can take to green your lab. Today, the pharmaceutical sector emits more...
by Dr. Alyssa Master | Jun 24, 2021
The surge of cellular T cell-based immunotherapies has prompted more and more researchers to take an interest in these specialized immune cells. Whether you are brand new to the cell therapy field or an experienced immunologist, learning to work with a new cell type...
![Kymriah vs. Yescarta [UPDATED]](https://nucleusbiologics.com/wp-content/uploads/2019/05/kymriah-vs-yescarta-feat.jpg)
by Dr. Alyssa Master | Aug 20, 2019
Kymriah® and Yescarta® are currently the only two FDA-approved CAR-T cell therapy products available on the market in the United States. Do you have trouble distinguishing between them? We created a simple chart to showcase some of the similarities and differences...
by Dr. Alyssa Master | Feb 9, 2019
Companies with breakthrough CAR T products need to focus not just on the science but also on how to successfully bring their therapies to market. Because cell and gene therapies are unlike conventional treatments, everything from sales & marketing to manufacturing...
